Tong Chi-Chung, Au Kwok-Hung, Ngan Roger Kai-Cheong, Cheung Foon-Yiu, Chow Sin-Ming, Fu Yiu-Tung, Au Joseph Siu-Kei, Law Stephen Chun-Key
Department of Clinical Oncology, Queen Elizabeth Hospital, 30 Gascoigne Road, Kowloon, Hong Kong, China.
Head Neck Oncol. 2012 May 18;4:23. doi: 10.1186/1758-3284-4-23.
To evaluate the clinical outcome of early glottic cancer (GC) treated by primary radiotherapy (RT) with 6 MV photons.
We retrospectively reviewed the medical records of 695 consecutive patients with T1N0 and T2N0 GC treated between 1983 and 2005 by RT in our institution. Clinical outcome in terms of local control (LC), overall survival (OS) and cause- specific survival (CSS) rate were evaluated.
The median follow-up time was 10.5 years. The 10-year actuarial LC rates were as follows: T1A, 91%; T1B, 87%; T2, 77%. The 10-year OS were as follows: T1, 74.2%; T2, 70.7%. The 10-year CSS were as follows: T1, 97.7%; T2, 97.1%.Poorly differentiated histology and tumor biologically effective dose<65 Gy15 were adverse factors in both LC of T1 and T2 disease. Involvement of anterior commissure was an adverse factor in both LC and CSS of T1 disease. Subglottic extension was associated with poor LC in T2 disease whereas hemoglobin <13.0 was associated with poor LC and CSS of T2 disease.
Primary RT remains an option among the various standard treatments for early GC. Clinical treatment outcome by 6MV photons is similar and comparable to historic data of Cobalt-60 and 2 MV photons.
评估采用6兆伏光子进行原发性放射治疗（RT）的早期声门癌（GC）的临床疗效。
我们回顾性分析了1983年至2005年间在我院接受RT治疗的695例连续T1N0和T2N0 GC患者的病历。评估了局部控制（LC）、总生存率（OS）和特定病因生存率（CSS）方面的临床疗效。
中位随访时间为10.5年。10年精算LC率如下：T1A，91%；T1B，87%；T2，77%。10年OS如下：T1，74.2%；T2，70.7%。10年CSS如下：T1，97.7%；T2，97.1%。组织学分化差和肿瘤生物等效剂量<65 Gy15是T1和T2期疾病LC的不利因素。前联合受累是T1期疾病LC和CSS的不利因素。声门下扩展与T2期疾病的LC差有关，而血红蛋白<13.0与T2期疾病的LC和CSS差有关。
原发性RT仍然是早期GC各种标准治疗方法中的一种选择。6兆伏光子的临床治疗效果与钴-60和2兆伏光子的历史数据相似且具有可比性。
